Staphylococcus Or Streptococcus (e.g., Pneumococcus Or Streptococcus Pneumoniae, Streptococcus Mutans, Etc.) Patents (Class 424/165.1)
  • Publication number: 20130052204
    Abstract: Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be conjugated to a T-cell dependent antigen. Also provided are methods for synthesizing PGP and methods for conjugating PGP to a T-cell dependent antigen.
    Type: Application
    Filed: November 15, 2010
    Publication date: February 28, 2013
    Inventors: Clifford M. Snapper, Andrew Lees, James J. Mond, David Schwartz
  • Publication number: 20130045211
    Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
    Type: Application
    Filed: January 5, 2011
    Publication date: February 21, 2013
    Applicants: THE ROCKEFELLER UNIVERSITY, CONTRAFECT CORPORATION
    Inventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
  • Patent number: 8377446
    Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 19, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Marco Soriani, Isabella Santi
  • Publication number: 20130017203
    Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.
    Type: Application
    Filed: June 19, 2012
    Publication date: January 17, 2013
    Applicant: NEW YORK UNIVERSITY
    Inventors: Victor J. TORRES, Francis ALONZO, III
  • Publication number: 20120322988
    Abstract: The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti-Staphylococcus aureus antibodies as the active ingredient. A therapeutic agent for psoriasis or atopic dermatitis is specifically provided. This agent comprises comprehensive anti-S. aureus surface antibodies, including antibodies against entire cell-surface proteins, as the active ingredient. The agent is obtainable by: (a) treating S. aureus with a protein crosslinking/fixation reagent to fix proteins expressed on the surface of S. aureus via intramolecular crosslinking; (b) administering S. aureus treated with the protein crosslinking/fixation reagent for protein fixation to an animal as an immunogen; and (c) obtaining an antibody from the animal.
    Type: Application
    Filed: November 12, 2010
    Publication date: December 20, 2012
    Inventor: Masayoshi Shichiri
  • Patent number: 8324354
    Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 4, 2012
    Assignee: Stichting Dienst Landbouwkundig Onderzoek
    Inventor: Hilda Elizabeth Smith
  • Publication number: 20120301481
    Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.
    Type: Application
    Filed: July 20, 2012
    Publication date: November 29, 2012
    Inventors: Michael Otto, Stanislava Kocianova, Cuong Vuong, Jovanka Voyich, Yufeng Yao, Elizabeth Fischer, Frank De Leo
  • Patent number: 8241857
    Abstract: To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: August 14, 2012
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Suguru Akamatsu, Yoko Saijo
  • Publication number: 20120201833
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 9, 2012
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Publication number: 20120201834
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 9, 2012
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Publication number: 20120195898
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: January 31, 2012
    Publication date: August 2, 2012
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Publication number: 20120177650
    Abstract: A method and composition for treating enteric pathogen infections in animals suffering from such infections or displaying diseases or conditions consistent with such infections or for preventing or reducing the likelihood of enteric pathogen infections in animals at risk for developing such infections.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 12, 2012
    Inventor: Thomas Julius Borody
  • Publication number: 20120171223
    Abstract: This invention provides antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Application
    Filed: January 3, 2008
    Publication date: July 5, 2012
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Patent number: 8211431
    Abstract: The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from Staphylococcus.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: July 3, 2012
    Assignee: Crucell Holland B.V.
    Inventors: Mark Throsby, Cecilia A. W. Geuijen, Cornelis Adriaan De Kruif
  • Publication number: 20120148601
    Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.
    Type: Application
    Filed: November 28, 2011
    Publication date: June 14, 2012
    Inventors: ROBERT G. ULRICH, Mark A. Olson, Sina Bavari
  • Publication number: 20120107327
    Abstract: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.
    Type: Application
    Filed: June 22, 2010
    Publication date: May 3, 2012
    Applicant: WYETH LLC
    Inventors: Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Steven Morris Baker, Jasdeep Singh Nanra, Ellen Murphy, Bruce Arthur Green, Mark Edward Ruppen, Yekaterina Timofeyeva
  • Patent number: 8163288
    Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: April 24, 2012
    Assignee: Absynth Biologics Limited
    Inventors: Simon J. Foster, Jorge Garcia-Lara
  • Publication number: 20120087930
    Abstract: The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting Streptococcus strains of the anginosus group, preferably for detecting Streptococcus anginosus and/or Streptococcus constellatus as well as for discriminating Streptococcus anginosus and/or Streptococcus constellatus from other streptococci. The present invention furthermore relates to these nucleic acids and polypeptides for use in the diagnosis and/or prognosis of infections with Streptococcus strains of the anginosus group. The present invention furthermore relates to methods utilizing these nucleic acids and polypeptides as well as to arrays and antibodies.
    Type: Application
    Filed: June 18, 2009
    Publication date: April 12, 2012
    Inventors: Gursharan S. Chhatwal, Patric Nitsche-Schmitz, Silvana Reissmann
  • Publication number: 20120082677
    Abstract: Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of hepatitis C infected patients.
    Type: Application
    Filed: October 1, 2010
    Publication date: April 5, 2012
    Inventor: Sherif Salah Abdul Aziz
  • Patent number: 8142780
    Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: March 27, 2012
    Assignee: STROX Biopharmaceuticals, LLC
    Inventor: Stanley Arthur Kim
  • Publication number: 20120027771
    Abstract: The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these compositions and methods involve human polyclonal antibodies affinity purified from human blood using certain viral, bacterial, eukaryotic protist and/or fungal antigens as described herein. Methods of making the antigenic preparations and the affinity-purified human polyclonal antibodies for passive immunization are also provided.
    Type: Application
    Filed: April 12, 2011
    Publication date: February 2, 2012
    Inventor: THOMAS L. CANTOR
  • Publication number: 20110305688
    Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.
    Type: Application
    Filed: October 7, 2009
    Publication date: December 15, 2011
    Applicant: STICHTING KATHOLIEKE UNIVERSITEIT, MORE PARTICULARLY THE RADBOUD UNIVERISTY NIJMEGEN MEDIC
    Inventors: Peter Wilhelmus Maria Hermans, Hester Jeanette Bootsma, Pieter Jan Burghout, Christian Ostergaard Andersen, Oscar Paul Kuipers, Johanna Jacoba Elisabeth Bijlsma, Thomas Gerrit Kloosterman
  • Patent number: 8071102
    Abstract: Novel vaccines include polypeptides that comprise regions corresponding to a chemokine and a hapten. The hapten can be an amino acid sequence corresponding to the Meningitis Related Homologous Antigenic Sequences (MRHAS) of bacterial and viral agents known to cause meningitis. Protective immunity in a host susceptible to meningitis can be induced by inoculating the host with immunogenic amount of such a vaccine.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: December 6, 2011
    Inventors: Diane Van Alstyne, Lawrence R. Sharma
  • Publication number: 20110274700
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Application
    Filed: May 9, 2011
    Publication date: November 10, 2011
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Publication number: 20110250202
    Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.
    Type: Application
    Filed: May 7, 2009
    Publication date: October 13, 2011
    Applicant: Innovative Biosensors, Inc.
    Inventors: Colette Cote, Qiao-Xi Zheng, Venkatakrishna Shyamala, Tom Hazel
  • Publication number: 20110217312
    Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 8, 2011
    Inventors: Michael Otto, Stanislava Kocianova, Cuong Vuong, Jovanka Voyich, Yufeng Yao, Elizabeth Fischer, Frank De Leo
  • Patent number: 8007803
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: August 30, 2011
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
  • Publication number: 20110195075
    Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which including the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present of the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administering. Compositions contain isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.
    Type: Application
    Filed: July 31, 2009
    Publication date: August 11, 2011
    Inventors: Edwin W. Ades, Gowrisankar Rajam, Sandra Steiner, George M. Carlone, Nikkol Melnick, Jacquelyn S. Sampson, Joseph E. Martinez, Julie M. Skinner
  • Publication number: 20110171224
    Abstract: Disclosed are pharmaceutical compositions that include a PsrP polypeptide, a nucleic acid encoding a PsrP polypeptide, or an antibody or fragment thereof that binds to a PsrP polypeptide domain, and methods of inhibiting, modulating, treating, or preventing a bacterial infection, such as an infection due to Streptococcus pneumoniae, in a subject using these compositions.
    Type: Application
    Filed: May 22, 2009
    Publication date: July 14, 2011
    Inventor: Carlos J. Orihuela
  • Publication number: 20110171237
    Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.
    Type: Application
    Filed: April 23, 2010
    Publication date: July 14, 2011
    Applicant: ABSYNTH BIOLOGICS LTD.
    Inventor: Simon J. FOSTER
  • Publication number: 20110091480
    Abstract: The present invention features antigen binding protein that bind an ORF0657n target region (SEQ ID NO: 1). ORF0657n is an S. aureus protein. ORF0657n target regions are provided by the mAb 1G3.BD4, mAb 2H2.BE11, mAb 13C7.BC1, and mAb 13G11.BF3 binding sites. In a lethal model challenge, mAb 2H2.BE11 and mAb 13C7.BC1 provided for increased survival against S. aureus infection. There was also protection demonstrated in an ex vivo model with either the IgG1 or the IgG2b form of mAb 2H2; and in a passive immunization murine indwelling catheter model using mAb 2H2.BE11.
    Type: Application
    Filed: January 23, 2007
    Publication date: April 21, 2011
    Inventors: Martha J. Brown, Annaliesa S. Anderson, Leslie D. Cope, Kathrin Ute Jansen, Tessie McNeely, Barrett R. Harvey, Eberhard Durr, Robin Ernst
  • Patent number: 7927607
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: April 19, 2011
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
  • Patent number: 7927605
    Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: April 19, 2011
    Assignee: Stichting Dienst Landbouwkundig Onderzoek
    Inventor: Hilda Elizabeth Smith
  • Publication number: 20110081347
    Abstract: This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Application
    Filed: June 4, 2009
    Publication date: April 7, 2011
    Applicant: MacroGenics, Inc.
    Inventor: Sergey Gorlatov
  • Publication number: 20110064745
    Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.
    Type: Application
    Filed: August 23, 2010
    Publication date: March 17, 2011
    Inventors: Michael F. Good, Michael R. Batzloff, Manisha Pandey
  • Publication number: 20110059085
    Abstract: A new antibody-based strategy for treating or preventing Staphylococcus aureus infections utilizes IgM antibodies specific for one or more Staphylococcus aureus capsular antigens. Examples of such antibodies include (i) a polyclonal IgM antibody composition that is isolated from pooled donor plasma and enriched for those IgMs that specifically bind Staphylococcus aureus capsular antigens or (ii) one or more IgM monoclonal antibodies that specifically bind Staphylococcus aureus capsular antigens.
    Type: Application
    Filed: November 11, 2010
    Publication date: March 10, 2011
    Applicant: STROX BIOPHARMACEUTICALS, LLC
    Inventor: Stanley A. Kim
  • Patent number: 7892552
    Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: February 22, 2011
    Assignees: University of Utah Research Foundation, St. Jude Children's Research Hospital
    Inventors: Elisabeth Adderson, John Bohnsack
  • Publication number: 20110038879
    Abstract: Compositions for preventing and/or treating S. pyogenes infection which comprise one or more active agents. The active agents are SLO antigens, nucleic acid molecules encoding the SLO antigens, and/or antibodies which selectively bind to the SLO antigens.
    Type: Application
    Filed: October 30, 2007
    Publication date: February 17, 2011
    Applicant: NOVARTIS AG
    Inventors: Maria Scarselli, Giuliano Bensi, Guido Grandi
  • Publication number: 20110033479
    Abstract: The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein ?1, and/or peptides comprising at least 5 consecutive amino acid residues of one of these autoantigenic proteins having immunological activity, or fragments, variants, or epitopes thereof and/or mixtures of at least two of the proteins and/or peptides as diagnostic tool for the detection of streptococcal driven conditions or as therapeutical agent for the treatment of streptococcal driven conditions.
    Type: Application
    Filed: September 29, 2008
    Publication date: February 10, 2011
    Applicant: LUDWIG-MAXIMILIANS-UNIVERSITAT
    Inventors: Jörg C. Prinz, Petra Besgen, Paul Trommler
  • Publication number: 20110027265
    Abstract: Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.
    Type: Application
    Filed: August 29, 2008
    Publication date: February 3, 2011
    Applicant: The University of Chicago
    Inventors: Juliane Bubeck-Wardenburg, Olaf Schneewind, Brook Ragle
  • Publication number: 20110020216
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.
    Type: Application
    Filed: June 11, 2008
    Publication date: January 27, 2011
    Inventors: David James Mooney, Omar abdel-Rahman Ali
  • Patent number: 7867501
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: January 11, 2011
    Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitee
    Inventors: Lynn Doucette-Stamm, David Bush, Oiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Publication number: 20100291177
    Abstract: The present application discloses antibodies directed to protein SE2232 (SesC) of Staphylococcus epidermis, and homologus proteins which are useful in preventing biofilm formation by said micro-organism. The antibodies can be used to coat medical devices which are inserted or implanted into the mammalian, preferably human body. Further these antibodies or vaccines comprising said proteins can be used to vaccinate subjects to prevent or treat natural occurring biofilm formation during infection. Also covered are medical devices coated with the antibody.
    Type: Application
    Filed: April 11, 2008
    Publication date: November 18, 2010
    Inventors: Peter Wilhelmus Maria Hermans, Johan Van Eldere
  • Publication number: 20100278819
    Abstract: Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and bacteraemia. It is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. The present invention provides a solution to this problem by providing a substantially pure or isolated disease related antigen selected from the group consisting of the isolated, recombinant or synthetic S. pneumoniae human immunogenic antigens of SP_0562, SP_0965, SP_0082 (in particular the fragments SP4 and SP 17 of said SP_0082), and a Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386), or a fragments thereof or substantially identical antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or against S. pneumoniae in a human.
    Type: Application
    Filed: September 15, 2008
    Publication date: November 4, 2010
    Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Xavier Bossuyt, Leen Moens
  • Publication number: 20100233185
    Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.
    Type: Application
    Filed: May 24, 2010
    Publication date: September 16, 2010
    Inventors: Patricia Denny, Paul C. Denny, Mahvash Navazesh
  • Publication number: 20100196379
    Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci.
    Type: Application
    Filed: December 7, 2009
    Publication date: August 5, 2010
    Inventors: Elisabeth Adderson, John Bohnsack
  • Publication number: 20100166772
    Abstract: The present invention features antigen binding proteins that bind to a region found to have an epitope that can be targeted to provide protection against S. aureus infection. The region is designated herein as the “CS-D7” target region. The CS-D7 target region provides an S. aureus ORF0657n epitope that can be targeted to reduce the likelihood or severity of an S. aureus infection.
    Type: Application
    Filed: May 29, 2008
    Publication date: July 1, 2010
    Inventors: Annaliesa S. Anderson, Desmond J. Clark, Zhiqiang An, Fubao Wang, Susan L. Secore, Eberhard Durr, Leslie D. Cope, Tessie McNeely
  • Publication number: 20100166732
    Abstract: The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S.
    Type: Application
    Filed: July 6, 2007
    Publication date: July 1, 2010
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Alexander von Gabain, Manfred Berger, Beatrice Senn, Michael Schunn
  • Publication number: 20100150943
    Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Gram positive Streptococcus serotypes and isolates. Adhesin island polypeptides of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS, GBS, and S. pneumococcal infections.
    Type: Application
    Filed: July 26, 2007
    Publication date: June 17, 2010
    Applicant: NOVARTIS AG
    Inventors: Guido Grandi, John Telford, Marirosa Mora, Cesira Galeotti, Daniela Rinaudo, Andrea Guido Oreste Manetti
  • Publication number: 20100092487
    Abstract: According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in Staphylococcus aureus, a method and a kit for detecting the toxin with the use of the antibody, and a pharmaceutical composition containing an antibody against a Panton-Valentine leukocidin toxin for treating PVL infection caused by Staphylococcus aureus containing PVL are provided. Also, an antibody which is capable of binding to Panton-Valentine leukocidin F and has no cross-reactivity to LukD and/or HlgB and an antibody which is capable of binding to Panton-Valentine leukocidin S and has no cross-reactivity to at least one of LukE, HlgC, and HlgA are provided.
    Type: Application
    Filed: July 3, 2007
    Publication date: April 15, 2010
    Applicants: JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, DENKA SEIKEN CO., LTD.
    Inventors: Kanenari Ohishi, Tadashi Baba, Keiichi Hiramatsu, Yasuo Nakatomi